WO2008140200A1

WO2008140200A1 - External compositions for the skin

Info

Publication number: WO2008140200A1
Application number: PCT/KR2008/002510
Authority: WO
Inventors: Seon-Il Kim
Original assignee: Seon-Il Kim
Priority date: 2007-05-10
Filing date: 2008-05-02
Publication date: 2008-11-20
Also published as: KR20100016450A; KR20070079596A

Abstract

The present invention relates to an external composition for skin containing sulfur and alum, which can be used as cosmetic or dermatological compositions to improve and treat various skin diseases. The present invention promptly improves skin damage and pruritus resulting from eczema, atopic dermatitis, tinea, pustulosis palmaris et plantaris, or wounds, without involving toxicity or side effects. The present invention has the effect of healing without leaving scars, and also the effects of skin-whitening and reducing and preventing wrinkles.

Description

EXTERNAL COMPOSITIONS FOR THE SKIN

CROSS-REFERENCE TO RELATED APPLICATION

The present application claims priority to and the benefit of Korean patent application No. 10-2007-0045375 filed on May 10, 2007 and Korean patent application No. 10-2007-0071689 filed on July 18, 2007 in the Korea

Intellectual Property Office, the entire contents of which are incorporated hereinto by reference.

BACKGROUND OF THE INVENTION

(a) Field of the Invention

The present invention relates to an external composition for skin containing sulfur and alum, which can be used as cosmetic or dermatological compositions to improve and treat various skin diseases. The present invention promptly improves skin damage and pruritus resulting from eczema, atopic dermatitis, tinea, pustulosis palmaris et plantaris, or wounds, without involving toxicity or side effects. The present invention has the effect of healing without leaving scars, and also has effects of skin-whitening and reducing and preventing wrinkles.

(b) Description of the Related Art

Cosmetics are used for the purpose of protecting skin, preventing skin diseases, and enhancing the wearer's appearance and cleaning. However, some ingredients that are undesirable in light of the above purposes are included as necessary components of cosmetic formulations and thereby cause skin diseases.

Known inflammatory skin diseases include atopic dermatitis, contact dermatitis, seborrhoic dermatitis, and acne. Atopic dermatitis, commonly known as eczema, is an eczema-like dermatological disorder found with atopic people. i The cause of atopic dermatitis is still unknown, but it seems to be related to a genetic factor. To date a dominant theory is that the disease is a kind of autoimmune diseases. Atopic dermatitis has distinctive symptoms and signs, which differentiates it from other common types of eczema and dermatitis. The disease accounts for 70—80% of infant eczema and recently has been frequently found in adults as well.

Conventionally, inflammatory skin diseases have been treated with antihistamine, vitamin ointments, and adrenocortical hormones. However, those treatments are problematic in that their pharmacological effects are temporary while having many accompanying side effects. Particularly, with regard to atopic dermatitis, various 5-lipooxygenase inhibitors have been suggested as potential agents for anti-allergic medicines, and it has been known that cromolyn sodium relieves allergy symptoms by negating the reaction of mast cells to allergens. Those substances, however, have failed to produce clinically significant effects.

For the treatment of acne, antibiotics such as erythromycin or estrogen to decrease the production of sebum have been widely used, but they are associated with some side effects. Cosmetics for acne treatment have included substances such as vitamin A derivatives, benzoyl peroxide, silisic acid, and triclosan, however, while these substances have produced some degree of anti-microbial effects, they have been associated with side effects including rubefaction and oversensitivity or photosensitivity of skin.

To resolve the problems as above, there is a need for an external composition for skin that is applicable as a beauty product as well as being capable of preventing and treating skin diseases.

SUMMARY OF THE INVENTION

An object of the present invention is to provide external compositions for curing or relieving skin diseases, with the purpose of solving the problems as noted above, which strongly prohibit the generation of cyclooxygenase-2 and free radicals, involves no toxicity or side effects, promotes the renewal of normal skin while leaving no scars, reduces formation of wrinkles, and possesses a good moisturizing effect.

Another object of the present invention is to provide external compositions for curing or relieving skin diseases, and which provide supportive functions for the treatment of skin diseases and functions requested for skin health such as enhancement of inflammation healing and cell revitalization, disinfection, relief of pruritus, prevention and relief of wrinkles, provision of long- lasting moisture, and maintenance and promotion of skin elasticity. Another object of the present invention is to provide an external composition for curing or relieving skin diseases, where the skin diseases to be treated by the composition can be dermal inflammations, acne, xerosis, tinea pedis, eczema, allergic rushes, pruritus, tinea, psoriasis, pustulosis palmaris et plantaris, or atopic diseases. Another object of the present invention is to provide an anti-microbial composition.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

These and other objects of the invention will be more fully understood from the following description of the invention, the referenced drawings attached hereto, and the claims appended hereto.

The present invention provides a pharmaceutical or cosmetic composition for curing or relieving skin diseases, which includes sulfur and alum.

The cosmetic composition for relieving skin diseases according to the present invention exerts a function of ameliorating damaged skin and the effect of skin rejuvenation in a manner explained below.

The ingredients of the composition according to the present invention penetrate into the cells in a damaged part and surrounding areas and disrupt bacterial membranes formed as a result of bacterial infection. Then the ingredients kill the bacteria. While maintaining the bactericidal process around the infected cells, the ingredients participate in the process of cell revitalization and promote blood circulation and physiological activities. They are engaged as intermediary substances in complicated reactions between the cells and substrates around the cells. In order for the damaged skin to recover, necessary nutrition has to be provided for the formation of cells and tissues in the damaged area. By promoting the formation of blood vessels, the ingredients enable rapid renewal of the skin. In addition, the ingredients of the composition according to the present invention remove calluses that are thickly formed on the skin as a result of skin diseases. Once the calluses are removed, effective ingredients are able to deeply penetrate into the cells in the damaged area, where the effective ingredients remove pain and itch by eliminating poisonous products generated by the bacteria and show the effects of reducing wrinkles and moisturizing dry skin.

By using a cosmetic composition for curing or relieving skin diseases according to the present invention, one can expect the effect of restoring to normal damaged skin caused by psoriasis, blistery tinea, various types of eczema, itch, shingles, chronic pruritus, pustulosis palmaris et plantaris, fungal tinea pedis, and malignant intumescence, as well as the effects of whitening, prevention and relief of wrinkles, moisturizing, and callus removal. Below is a further detailed description regarding the external composition for skin according to the present invention, a method of making the same, and functions of the same.

The external composition for skin according to the present invention includes sulfur and alum. Preferably, the composition includes 0.001-5.0 parts by weight of sulfur and 0.5-8.0 part by weight of alum per 100 parts by weight of a carrier.

Alum can be provided in a form dissolved in water, tree sap, or deep ocean water. The tree sap can be obtained from a living tree belonging to the group consisting of Bambusoideae, Aceraceae, Actinidiaceae, Elaeagnaceae, Alnus japonica, and Betulaceae. Alum has effects of healing furuncles and wounds, and of removing moisture and oils. For the present invention, both burnt alum and fresh alum can be used, alone or in combination.

The sulfate to be used for the prevent invention can be manufactured in a form included in an alkaline aqueous solution. It is preferred that the sulfate is dissolved in an alkali metal solution or a solution prepared with ignited shell powders from the outer shells of snail, abalone, shellfish, and waste coral

(hereinafter "waste shell" collectively).

Phellodendron amurensis extract, extractable from the bark of

Phellodendron amurensis, includes berberine, which has anti-rotting and antibacterial properties without allowing gram-positive, gram-negative bacteria and Neisseria gonorrhoeae to obtain resistance to the anti-infectant.

Depending on the types of skin diseases, other antibiotics can be used instead of Phellodendron amurensis extract. At least one antibiotic to be included in the composition can be selected from the group consisting of aminoglycoside, tetracycline, penicillins, cephalosporin, microrides, polypeptide, lincosamide, sulfon amide, and fluoroquinolone antibiotics.

In an embodiment of the present invention, the external composition for skin further includes at least one selected from the group of 0.5 to 8.0 parts by weight of cholesterol, 0.1 to 3.0 parts by weight of gypsum, 0.3 to 3.0 parts by weight of talc, and 0.5 to 5.0 parts by weight of pearl powder, per 100 parts by weight of a carrier.

Pearl powder is water-soluble and rich in minerals and bioactive substances. It has functions of maintaining low acidity and moisture on skin, enhancing immunity of skin, improving blood flow, and encouraging cell rejuvenation.

Gypsum helps in discharging unnecessary water out of the body at the damaged skin area, thereby drying mucosa resulting from deceases such as eczema and cooling the heat. No harm, toxicity, or side effects of gypsum are known. Potassium hydroxide has the capability of disrupting protective membranes for bacteria formed with secretions around the damaged skin, and is used as a cleanser in removing impurities and as a disinfectant.

Cholesterol has ability of quickly coagulating impurities of mucosa, as gypsum does, and acts on damaged blood present in peripheral arteries, thereby allowing agents working on the extravagated blood to be engaged in the process of purifying the blood.

Gypsum, when applied on damaged skin, removes impurities on the skin and coagulates mucosa, resulting in a protective cap around the damaged area, thereby providing a skin protection function. The external composition for skin can further include at least one ingredient selected from the group consisting of plant extracts, seaweeds extracts, animal extracts, minerals or extracts thereof, chemicals or general- purpose regenerative chemicals made of those chemicals, anti-bacterial agents, germicidal agents, moisturizing substances, nutrients, wrinkle-relieving substances, pruritus-relieving substances, anodyne, harmonic substances, blood circulation-improving agents, and anti-allergic substances.

In the above composition, a plant extract can be included at 0.1 - 30 parts by weight per 100 parts by weight of a carrier. The plant extract can be a solvent extract extracted using at least one solvent selected from the group consisting of water, an alkali solution, and a C1-C4 alcohol. Alternatively, the plant extract can be a plant oil.

Examples of plant extracts or plant oils can be at least one selected from the group consisting of bluet, Sasa Vetchii, Lonicera japonica, horsetail, Stellaria medium, comfrey, persimmon leaves, rice bran, mulberry tree, cocoon, branch, Thladiantha dubia, hardy (trifoliate) orange, apricot, peach leaves, Benicasa hispida, pomegranate, Cupressaceae, Lespedeza bicolor, Maximowiczia chinensis, Plantago asiatica, Ligularia fischeri, Opuntia, Taraxacum mongolicum Hand-mazz, Scutellaria baicalensis G, Selaginella Tamariscina, Schizonepeta tenuifolia. var. Japonica, Coptidis Rhizoma, Commiphora molmol, Cinnamomum cassia, Angelica, Portulaca oleracea L, gingko nut, garlic, carrot, adlay, Centella asiatica, spring onion, grapefruit, rhodea, Artemisia iwayomogi, green tea, rose of Sharon, hollyhock, Saxifraga laciniata, cactus, husks, chrysanthemum, chestnut skin, Bower Actinidia, ginseng, SaNx koreensis, walnut, a Japanese apricot, Xanthium strumarium, Forsythia koreana, (garden) balsam, Sophora angustifolia Sieb, Portulaca oleracea, Korean knotweed, Aconitum pseudo-laeve var, Beombuche, Solanum nigrum, Scrophularia buergeriana, Lithospermum erythrorhizon, Rubia akane Nakai, rose, Sambucus sieboldiana, trichophytia, Fraxinus sieboldiana, Pinellia ternata, Oenothera odorata, Elaeagnus umbellate, Centella Asiatica, Salicornia herbacea L., Glycyrrhiza uralensis, Callicarpa japonica Thunberg, Mirabilitum Depuratum, Paeonia lactiflora, lily, Youngreunghyang, Chamaecyparis obtusa, Arctium lappa, fruits including apples and grapes, mushrooms, beans, Adenophora, ldesia polycarpa, Ardisia crenata, Symplocos chinensis for. pilosa, Nigeulroseuporaseuperika, Zanthoxylum piperitum, Dianthus caryophyllus, Equisetum giganteum, Canna generalis, astaxanthin, Malpighia glabra, Asterias amurensis(sea star), Pinus densiflora, Betula platyphylla var. japonica, Chamomile, Marigold, Rosmarinus officnalis L. , Mentha piperita (Peppermint), Melissa officinalis (Lemon Balm), Douglas-fir, Jasminum (jasmine), propolis, Allantoin, Melaleuca alternifolia, and Labiatae. The composition according to the present invention can further include at least one anti-inflammatory agent selected from the group consisting of flufenamic acid, ibuprofen, benzydamin, indomethacin, prednisolone (steroid), and dexamethasone, the anti-inflammatory being included at 0.0001-2.0 parts by weight in 100 parts by weight of a carrier. The composition according to the present invention can further include at least one antibiotic selected from the group consisting of Aminoglycosides, Glycopeptides, Tetracyclines, Spectinomyxin, Bacitracin, Polymyxin, and Fosfomyxin, the anti-antibiotics being included at 0.0001-2.0 parts by weight with respect to 100 parts by weight of a carrier. The composition according to the present invention can further include at least one extract obtained from the group consisting of earthworms, frogs, lizards, snakes, centipedes, ants, animal skin, animal's internal organs, and animal placentae. Examples of seaweeds that can be used for the present invention are brown seaweed, kelp, corals, and Salicornia herbacea. Seaweed extracts that can be used for the present invention include carrageenan, alginic acid, sodium alginate, and potassium alginate, which are obtainable by purification of seaweed materials. One can use conventional purification methods to obtain those seaweed extracts.

Examples of minerals that can be used for the present invention are mica, gold, calcium, silicic acid, yellow soil, and sea soil.

An illustrative method for preparing the external composition for skin according to of the present invention is provided below. Alum is dissolved in water, tree sap, plant extract, or deep sea water to prepare a solution. Sulfur is prepared in a form dissolved in an alkaline aqueous solution. By injecting the above-prepared alum and sulfur solutions into a porous carrier, alum and sulfur are induced to be absolved in the carrier. The alkaline aqueous solution used to prepare the sulfur solution can be an alkali metal solution or can be obtained from ignited shell powder of snail, abalone, shellfish, and coral.

The above porous carrier can be zeolite, or can be prepared from shells of snail, abalone, shellfish, and coral. The shells are heated to a high temperature, cooled, and finally crushed to powder. By adding water to the above-prepared powder and heating it, an alkaline aqueous solution can be obtained.

Shell powder possesses strong alkaline properties, and most of its kinds include calcium. A strong alkaline aqueous solution prepared from shell powder, which retains oxygen in a large amount, provides oxygen to the cells in the damaged skin area, and engages, as an antioxidant, in the normalization process of the autoimmune condition, revitalizes cells, and relives symptoms of pruritus. Applied on skin, the shell powder causes no pain or harm and has no toxicity while being a strong antimicrobial material. It is capable of liquefying silver and sulfur. Solvents can be used to manufacture the external composition for skin according to the present invention. Examples of the solvents are water, tree sap, and deep sea water.

The external compositions for skin according to the present invention can be pharmaceutical compositions. The compositions of the present invention generally include pharmacologically acceptable carriers. Examples of carriers to be used for topical application, which is useful for the practice of the present invention, include - but are not limited to - alkylene glycol, and a mixture of alkylene glycol and at least one derivative of hydroxyalkyl cellulose.

The compositions according to the present invention can be formulated and then administered in forms appropriate for drug delivery. The compositions can be easily administered in various forms (direct topical application, application of patch for transdermal delivery, etc.) The amount of dose administered can be determined depending on the condition of the disease to be treated. The external compositions for skin according to the present invention can be cosmetic compositions, which can be provided in the form of skin gel, cream, lotion, powder, foundation, essence, gel, foam cleanser, soap, cleansing oil, powdery foundation, suspension foundation, or wax foundation.

Effective ingredients to be included in the external compositions for skin according to the present invention can be conventionally-used substances for cosmetics, in addition to the above-explained extracts. Thus the external compositions for skin according to the present invention can further include at least one additive selected from the group consisting of vitamins, amino acids, proteins, surfactants, emulsifiers, stabilizers, thickening agents, preservatives, moisturizers, anti-oxidants, perfumes, and pigments. Depending on the needs for which the external compositions for skin according to the present invention is applied, other conventional cosmetic ingredients can be further included, in addition to the above necessary ingredients. Other additives, without being restricted to the above-cited materials, can be included in the external compositions for skin according to the present invention.

The present invention is further explained in more detail with reference to the following examples. These examples, however, should not be interpreted as limiting the scope of the present invention in any manner.

EXAMPLE 1 : Preparation of compositions for skin

For providing embodiments of the compositions for skin according to the present invention, methods for manufacturing three kinds of compositions are detailed below.

1-1. SBC Composition

A. Preparation of Waste Shell Powder

To prepare waste shell powder and its alkaline aqueous solution, 10Og of snail shell waste was heated at approximately 1500 ^"C in a heating chamber and subsequently cooled to room temperature. The shells were crushed into powder and separated with a screen to obtain a particle size of about 40 mesh.

500ml of distilled water was added to the powder, which was then stirred for 30 minutes at about 100⁰C . By applying a method of solid-liquid separation to the mixture, porous powder of shell waste and an alkaline aqueous solution were obtained.

B. Preparation of sulfur- and alum-absorbed material

0.15g of sulfur was dissolved in 5ml (5cc) of the above-prepared alkaline aqueous solution (ph12-13.5) or a potassium hydroxide solution, which is made by dissolving 0.3g of potassium hydroxide in 5ml of distilled water. An alum solution was prepared by dissolving 0.5g of alum in 10ml of birch sap, collected from birch trees.

8g of the above-prepared waste shell powder or zeolite was placed in the vacuum chamber. Then the above-prepared sulfur solution and the alum solution were added into the chamber. After adjusting the pH of the chamber to 5-7, the materials was stirred and mixed together. With the vacuum inside the chamber decreased slowly, sulfur- and alum-absorbed material was obtained. To adjust pH in the chamber, citric acid or potassium hydroxide was used.

C. Formation of composition SBC Subsequently, a base mixture including 2Og of general-purpose stearic acid, 2Og of glycerin, and 6Og of birch sap was placed in the heating chamber and stirred at a temperature below 70 "C for about 10 minutes. The resulting base mixture was injected into the vacuum chamber, in which the sulfur- and alum-absorbed material was placed, and was stirred and mixed under heat (below 70⁰C). The materials were cooled to obtain the composition SBC according to the present invention.

1-2. Composition SBCO-1

The composition SBCO-1 in the present example includes pine resin, borax, camphor, silver, and Phellodendron amurensis as effective components, in addition to sulfur and alum contained in the above SBC.

0.35g of pine resin and 0.25g of camphor were dissolved in 10ml of alcohol. 0.2g of borax was dissolved in 5ml of distilled water. For silver, a silver ion solution (purity= 99.99%, c = 0.001 g/L, particle size = 5nm) was used. For Phellodendron amurensis, a water extract obtained by evaporation was used.

In a manner substantially similar to that of Example 1-1 , vacuum-treated waste shell powder or zeolite was stirred and mixed together with pine resin, borax, camphor, silver, and Phellodendron amurensis extract, in addition to the sulfur solution and the alum solution, to obtain the composition SBCO-1 according to the present invention.

1-3. Preparation of the Composition SBCO-2

The composition SBCO-1 in the present example further includes cholesterol, pearl powder, talc, and gypsum as effective components, in addition to sulfur, alum, pine resin, borax, camphor, silver, and Phellodendron amurensis included in SBCO-1.

In a manner substantially similar to that of Example 1-1 , vacuum-treated waste shell powder or zeolite was stirred and mixed together with 0.2g of cholesterol, 0.5g of pearl powder, 0.3g of talc, and 0.1g of gypsum, in addition to the sulfur solution and the alum solution, pine resin, borax, camphor, silver, and Phellodendron amurensis extract, to obtain the composition SBCO-2 according to the present invention.

Example 2: Effects on the Activity of Cycloxygenase-2

2-1 : Inhibitory Effect on Cyclooxygenase-2

An experiment was performed to assess the effects on cycloxygenase-2 activity of the compositions according to the present invention.

RAW 264.7 cells were grown (Chi), to which lipopolysaccharides were added. 24 hrs after the addition, the activity of cyclooxygenase-2 was assayed by ELISA for prostaglandin E2, an arachidonic acid metabolite generated by cyclooxygenase-2. The amounts of prostaglandin E2 as quantified by ELISA are indicated in Table 1.

A direct inhibitory effect on cyclooxygenase-2 was assayed. 24 hrs after the lipopolysaccharides treatment, the cells were rinsed and arachidonic acid and compositions made in Examples 1 and 2 were added to the cells. The results were assessed 30 minutes thereafter. The process was repeated three times. The results are shown in Table 1 ((Biochem Pharmacol. Vol. 61. pp1195-1203, 2001). [Table 1] Inhibitory effect on the production of prostaglandin E2 in RAW264.7 cells

As shown in Table 1 , the results show that the compositions according to the present invention inhibited the production of prostaglandin E2 at 25μg/m. of administration dose, which involved no cytotoxic effects.

As shown in the 30-minutes result, the compositions according to the present invention directly inhibited cyclooxygenase-2 activity.

2-2: Inhibiting Effect with the Activity of Cvclooxygenase-2 To prepare a substrate, 1100μM of arachidonic acid and 25μg of hemoglobin were added to Tris-buffer (0.1 M solution, pH 8.0). The above- prepared SBC, SBCO-1 , and SBCO-2, respectively, were added to the substrate and cyclooxygenase-2 (10,000 units) with different concentrations. Cyclooxygenase-2 activity was monitored by measuring initial oxygen consumption amounts (Yellow Spring Instrument Company, Model 53 oxygen monitor). The results are shown in Table 2. [Table 2]

Note: *N=3

Table 2 shows that the composition of the present invention has excellent inhibiting effects with the activity of cyclooxygenase-2.

Example 3: Anti-inflammatory Effects

To assess anti-inflammatory effects of the compositions of SBC, SBCO-1 , and SBCO-2 according to the present invention, a method using arachidonic acid was used (A. Crummey, G. P. Harper, E. A. Boyle, and F. R. Mangan. Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compound. Agents and Actions 1987: 20: 69-76).

35 hairless mice were provided. After cleansing their ears with alcohol, the ears' thickness was measured with a micrometer. The 35 mice was divided into five groups of 7 mice, including two experimental groups (treated with 0.5% and 1.0% of the compositions of the present invention, respectively), one comparative group (treated with 1.0% indomethacin), and one control group (treated with arachidonic acid). The respective materials were constantly applied to each group for four hours (once a day). The compositions of the present invention were applied to the two experimental groups (20 μi of each of the compositions), with indomethacin applied to the comparative group (20 μi) and ethanol applied to the control group (20 μJl). One hour after the last application, ethanol was applied to the left ears, with arachidonic acid applied to the right ears (2mg/ear). The development of edema on both ears was observed with a micrometer three times. The right ears of the mice in the experimental group were used to measure the intensity of inflammation induced by the test materials themselves. The control group, for which only arachidonic acid was applied, was used to measure the anti-inflammatory effect (the degree of edema inhibition).

[Table 3]

Inhibition Rate (%) = (A-B) / A x 100

A: Change in the average thickness of ears in the control group (thickness of ears treated with arachidonic acid - thickness of non-treated ears)

B: Change in the average thickness of ears in the experimental groups (thickness of ears treated with test materials - thickness of ears not treated)

As indicated in Table 3, 1.0% SBC and SBCO showed high inhibition rates of 59.2% and 61.3%, respectively, suggesting that their inhibition effects are more excellent than that of lndomethacin. When significant difference tests were conducted for the edema increase rates, SBC, SBCO-1 , and SBCO-2 were found to have significant differences compared to arachidonic acid and lndomethacin.

Example 4: Antibacterial Effect 4-1 : Antibacterial Effect on Gram-positive Cocci

To assess antibacterial ability of the compositions according to the present invention, Staphylococcus intermediusrbs known to cause atopic dermatis was used. This bacterial strain is the most commonly isolated strain from pyoderma, which causes both superficial and deep pyoderma. Thus it was used to assess the effects of the compositions according to the present invention on Staphylococcus, one of the manor pathogenic bacteria of skin diseases. Specifically the experiment was performed as shown in Table 4.

1) Bacterial strain used: Staphylococcus intermediusrbs, which was isolated from eczematous corporis, a kind of atopic dermatis.

2) Methods: 2 colonies of Staphylococcus cluster cultured on a blood medium were suspended in 30ml of distilled water and diluted 1 :1000.

Negative Control: 10ul of bacterial suspension added to 9.99ml of saline.

Positive Control: 10ul of bacterial suspension added to 9.99ml of saline in which cephalexin in a final concentration of 100mg/ml was included.

Experimental Groups: 10ul of bacterial suspension added to 2 mg of respective SBC, SBCO-1 , and SBCO-2.

Reactions were performed over the above groups. Results in the colonies were monitored for each group at intervals of 10 minutes, 30 minutes, and 1 hour after the reaction (plate method).

3) Results: all reactions were found to exert the effect of 100% inhibition on bacterial proliferation.

[Table 4] Experimental Method

[Table 5] Comparison of antibacterial effects on gram-positive cocci among the groups

As shown in Table 5, no proliferation of Staphylococcus was observed in the negative control group, in which no antibiotics were added. In the positive control group, in which Cephalexin was added as an antibiotic, proliferation of the bacteria was 100% inhibited at 10, 30 and 60 minutes. Consequently, it was confirmed that the compositions of SBC, SBCO-1 , and SBCO-2 possess antibacterial abilities as to gram-positive cocci, and particularly to Staphylococcus.

4-2: Antibacterial Effects on Gram-negative Cocci

Escherichia coli (E. coli), which was isolated from the urine of a sick dog contracted with a urinary disease, was used for the experiment.

1) Bacteral strain used: Escherichia coli (E. coli)

2) Method: two colonies of Staphylococcus cluster cultured on the blood medium were suspended in 30ml of distilled water and diluted 1 :1000.

Negative Control: 10ul of bacterial suspension added to 9.99ml of saline.

[Table 6] Experimental Method

[Table 7] Comparison of antibacterial effects on gram-negative cocci among the groups

As shown in Table 7, no proliferation of E. coli was observed in the negative control group in which no antibiotics were added. In the positive control group, in which Cephalexin was added as an antibiotic, proliferation of the bacteria was 100% inhibited at 10, 30, and 60 minutes. Consequently, it was confirmed that the compositions of SBC, SBCO-1 , and SBCO-2 possess antibacterial abilities as to gram-negative cocci, and particularly to, E. coli.

4-3: Antibacterial effects on Staphylococcus aureus

Staphylococcus aureus is known as one of pathogenic bacteria of atopic dermatitis. ATCC (American Type Culture Collection) 6538 of Staphylococcus aureus was used to assess the antibacterial effects on Staphylococcus aureus of the compositions according to the present invention. Based on the BHI

(Brain Heart Infusion) medium, the medium to be used for the experiment was constructed as shown in Table 8. After culturing the cells in the medium constructed as such, the number of living bacteria was UV- spectrophotometrically measured at 420 nm. The results are shown in Table 8. [Table 8] Absorption levels changing over cultivation time

A: SBCO-2 0.8g/100ml medium, B: neomycin 0.01 g/100ml medium C:

SBC 0.8g/100ml medium, D: polymixin 0.01g/100ml medium, and E: BHI medium.

In the medium shown in Table 8, the amount of SBC used was 0.8g per 100ml of medium. As indicated in Table 8, medium A and C, in which SBC was contained, showed no bacterial growth until 27 hours had elapsed. In medium B, in which neomycin was contained, bacterial growth rate was substantially suppressed for at least up to 12 hours, when compared to medium D, which used polymixin, or E, which merely used the basic BHI medium. Particularly, medium A, which used SBCO-2, showed a more intensive effect of inhibition on the bacterial growth.

4-4: Antibacterial Effects on Acne Pathogens

Propionibacterium acne, KCTC (Korean Collection for Type Cultures) 3314), which is known as a pathogen of acne, was grown on a medium constructed as shown in Table 9, which was based on Wilkins Chalgren Anaerobe Broth. After culturing the cells in the constructed medium, the number of living bacteria over time was UV-spectrophotometrically measured at 420 nm. The results are as shown in Table 9.

A: SBC 0.8 g / 100 ml medium, plus1.85 g of trisodium phosphate B: Polymixin 0.8 g/100ml medium C: SBCO-2 0.8 g /100ml medium D: Neomycin 0.08g/100ml medium E: Medium control

As shown in Table 9, A and C mediums in which SBC was used showed high level of antibacterial effects.

Example 5: Animal Tests to Assess Effect on Skin Diseases

5-1 Experimental Animal

A 2yr old dog contracted with atopic dermatitis, micosis, and tinea, the treatment of which was abandoned at hospital, was used. Until the date of the experiment, the dog was provided with brand name solid food (addition of antibiotics unknown) and a sufficient amount of water. It was allowed to become adapted to the environment for three days, in which temperature of 22± 2 and humidity of 55± 15% were maintained.

When diagnosed by the naked eye, damage was found in the dermal and hypodermic tissues, one at the lower neck area below the left ear sized 5.3cm in diameter, 3.2cm in width, and 5mm in depth, and the other at the lower neck area below the right ear sized 7.2cm in diameter, 5.2cm in width, and 6mm in depth. On the epithelium, substantial damage of 2-3mm in keratinocytes was observed by the naked eye, with some inflammation findings. At five points across the region ranging from left and right parts of the chest through the abdomen to the back femoral region, necroses were found to progress due to alopecia areata at 2-8 cm, centrifugally extending erythema, and white epidermal sloughs.

Pathological materials, including blister membranes, skin surface scales, and cellular tissues, were collected from the injured areas. Those materials were cut to 3-5mm specimens and were placed on slides. After a drop of 25 percent potassium hydroxide was added to each slide, a cover slip was placed thereon. After the specimen's keratinocytes were dissolved, microscopic examination was performed. It was confirmed that the infections were by tinea and mycosis. More specifically, microscopic findings were that the damage around the neck were atopic dermatitis and vesicular tinea caused by tinea and that the damage around the region from the chest to the back femoral region were a complication of infection by mycosis and generalized tinea.

5-2: Test Materials SBC, SBCO-1 , and SOCO-2 as manufactured according to the above examples of the present invention were used as test materials.

Tests were performed over the damage areas in the same single experimental subject, which are supposed to possess the same biochemical properties. Control groups to be used for this experiment can be either the side of the left and right neck areas of the sick dog. The left side of the neck was chosen for this experiment. Among the five points where necroses occurred, the two points were chosen for the control group - lesions on the left side infected by tinea and mycos.

5-3: Treatment of the Lesions

With the movement of the experimental animal restricted, the left-side lesions and surrounding areas were sterilized with alcohol. Hairs around the lesions were removed, and alcohol was applied again. The animal was locally anesthetized with 2% lidocaine HCL. The lesions were cleansed with gauze and hydrogen peroxide. After the keratocytes facing the derma were removed, the lesions were sprayed with alcohol and air-dried. A mixture of SBC, SBCO- 1 , and SBCO-2 (with equal parts of each) was applied to the lesions. The lesions were then wrapped with the gauze. With a protective strap around the neck, the neck was protected from contact with the back legs. Meanwhile, the skin where the necroses occurred had 2-3mm of keratocytes. After hairs were first removed in a similar manner as above, the keratocytes were abrasively scrubbed with diamond paper until they get thin. The scrubbed areas were then sprayed with alcohol and dried. Then the SBC mixture was lightly patted over the lesions such that acting ingredients of the compositions could penetrate inside the skin. SBCO-2 was then applied again. The treatment was repeated three times a day.

For the clinical treatment of the control group, a complex ointment was applied three times/day, and was made a mixture of teramycin ointment, neomycin ointment, variotin (a treatment for tinea), griseofulvin (antibiotic), a steroid ointment, an antihistamine ointment, centellasiatica to help rapid restoration of wounds, and elidel (immune-suppressive drug). The two infection sites by mycosis were treated in an identical manner.

5-4: Results In comparison with the control groups, the results of the treatment are as follows. a) Observation of the Control Group (Three days after treatment)

When observed with the naked eye, the lesion at the right side of the neck showed some hypodermal bleeding, while the inflammation and the size of the lesion were a bit reduced. At the two points in the regions ranging from the left chest to the femoral region, where necroses were progressing, small blisters on the erythematous skin were found to have disappeared. The centrifugal extension of erythema was also observed to have ceased. The experimental subject showed a decreased tendency of scratching the neck with the back leg and of rubbing the right side of the body against the wall. (Ten days after the treatment)

When observed with the naked eye, the lesion on the left side of the neck had stopped bleeding, and the dimension of the lesion was reduced to 6.8cm in length, 4.5cm in width, and 5mm in depth. The areas infected with tinea and mycosis were colored light red.

(Thirty days after the treatment)

The depth of the damage at the lesion on the neck was decreased, but the skin was in such a dry condition that it developed injurious cracks and a dark-red color, suggesting that the damage was being re-aggravated. No change was found in the areas infected with mycosis and tinea.

b) Observation of the Group Treated with the Compositions According to the Present Invention Observation was made for the groups treated with SBC, SBCO-1 , and

SBCO-2, in combination, which are manufactured according to the present invention. The observations were as follows. (Three days after treatment)

No bleeding or secretions accumulated were observed around the damage on the neck, nor was any inflammation found. The lesion was lightly pink-colored and, when observed with the naked eye, showed a good development of new blood vessels and collagen at the hypoderma. At the areas infected with mycosis and tinea, the skin showed no re-generation of thick keratinocytes and was colored light orange. (Ten days after treatment)

The dimension of the lesion was decreased to 2.6cm in length, 2cm in width, and 2.6mm in depth, with no inflammation findings. The experimental subject showed no behavior of scratching the damaged skin with the leg. At the area infected with mycosis and tinea, the color of the keratinocytes was turning white, and the centrifugal erythema was reduced in size.

(Thirty days after treatment)

The damage on the neck presented the same color and the same moisture level as found in the normal skin. The erythema disappeared at the areas infected with mycosis and tinea, where instead short hairs were observed to grow. This observation confirmed the curative function of the treatment. No recurrence of the infection was thereafter found.

c) Comparison of curative function between the control group and the group treated with the compounds 30 days after the first treatment, blood samples were collected from the control group and the experimental group (the group treated with the compounds according to the present invention). Each sample of approximately 100μ£ of blood was centrifuged for 20 minutes at 6500 rpm. From each sample, 30[il of serum was separated and was assayed using ELISA kits (R&D system) for serum concentration of IgE. [Table 10]

The result demonstrated the curative effects of the present invention on the infection with mycosis and tinea and restorative effects on the damage in epidermal, dermal, and hypodermic tissues. As shown in Table 10, increases of serum IgE concentration, which is characteristic of atopic dermatitis, was observed in the control group and contrasted with the level in the experimental group, which was close to a normal level. This suggests that the present invention is effective in the treatment of atopic dermatitis, eczema, and dry skin.

Since the compositions were found to engage in the immune system of skin, a possibility was also found to use the present invention for the treatments of intractable immune-related skin diseases, such as psoriasis and pustulosis palmaris et plantaris.

Example 6: Clinical Treatment Results

SBC ointments were applied to groups of patients, each group consisting of ten patients having the following diseases of atopic dermatitis, psoriasis, blistery tinea, various eczema, malignant acne, itching, shingles, psoriasis, chronic pruritus, palmoplanar pustulosis, or tinea pedis. The applied skin areas were gently patted and massaged.

1. Shingles

Application was performed at least two times a day, in the morning and afternoon, for 6 consecutive days. Among the patients treated, some degree of healing occurred in two patients, while almost complete healing occurred in the remaining 8 patients.

2. Atopic Dermatitis

Application was performed for seven patients having chronic atopic dermatitis, three times a day. After the first application, distinctive healing was observed in five patients in 3-5 days, complete healing in 10 days, and complete rejuvenation of skin in 30 days. For the remaining two patients, pruritus disappeared the day after the first application, some healing was observed in 26 days, and complete healing occurred in three months.

Application was made for three patients having initial atopic dermatitis, two times a day. As soon as the application and massage were performed, itching disappeared. From the time when 6 days passed after the first application, application was performed three times per a day, and two times per a day after 10 days had passed. In 60 days, no application was performed and complete healing was achieved.

Application was performed two times per day for two children suffering from atopic dermatitis (three years of history). As soon as the application and massage were performed, itching disappeared. Erythema disappeared after two days of treatment. In sixty days, complete healing was achieved, and further application was discontinued.

3. Palmoplanar pustulosis

Application was performed to patients who developed palmoplanar pustulosis, which is characterized by the symptoms of thickened palms and fissures thereon. The group of patients consisted of one patient with five years of history, five patients with nine years of history, and one patient with 12 years of history. The composition according to the present invention was applied to the patients and massaged into the skin, three to four times per a day for a week. In a week, the black-colored damaged skin turned red and was softened. Each of the patients treated experienced a full recovery and presented almost normalized skin.

4. Tinea Pedis

Application and massage was performed to patients whose skin was damaged due to three to seven years of tinea pedis. In 32 days, normal skin was completely re-formed. 5. The compositions according to the present invention were applied to skin infected with psoriasis and blistery tinea and were massaged into the skin, for 180 days. The skin was completely rejuvenated.

6. The compositions according to the present invention were applied to skin infected with allergic pruritus and were massaged into skin, for 12 days. As soon as the application was performed, itching was substantially improved. Pruritus completely disappeared in two months.

7. Skin affected by contact dermatitis develops small rashes and irritation.

The compositions according to the present invention were applied to the skin affected by contact dermatitis and massaged into the skin, three times/day. In 10 days, blisters and irritation disappeared.

8. For skin infected with shingles, which occurred on the upper part of the body and was previously treated with no effect, the compositions according to the present invention were applied two times/day. The skin was completely recovered in three days.

Example 7: Toxicity Test

7-1 : Animal Experiment

For the purpose of verifying the primary stability as raw materials of SBC, SBCO-1 , and SBCO-2, an MTT assay [reference: Mossman T. (1983). Rapid colorimetric assay for cellular growth & survival: application to proliferation & cytotoxicity assays. Journal of Immunological Methods65, 55~63] was performed on V79-4 cells (the Chinese hamster lung fibroblast cell line). Cytotoxic effects as measured are shown in Table 11.

[Table 11]

IC50: Inhibitory Concentration 50 (the concentration required for 50% cell kill)

As shown in Table 11 , IC50 values are 0.10 for SBCO-2, 0.11 for SBCO- 1 , and 0.13 for SCB, meaning that each of them showed 200 times lower levels of cytotoxicity than SLS and thus have excellent stability. In fact, the compositions' cytotoxicity levels were similar to that of squalene, which has good stability.

7-2: Acute or Chronic Toxicity Experiment a) Experiment Animal: rats of SPF SD line, female and male, aged 4 weeks. The rats, after being purchased, were housed in the laboratory for one week. Only animals that were healthy during one week of observation were used. Five females and five males were used. For the observation period, the animals were provided with solid food for lab animals and spring water. b) Method: SBC, SBCO-1 , and SBCO-2 manufactured according to the embodiments of the present invention were directly applied to the hair-removed skins. 10 hours after the application, the skins were rinsed and then dried before a re-application was made. The total duration given for the treatment was 30 days for each of the compositions of SBC₁ SBCO-1 , and SBCO-2. The method is further detailed in the following.

1) Observation of general conditions and mortality.

For the date when the application was made, the animals were observed hourly for their general conditions. For the following days, the animals were carefully observed for changes in general conditions including symptoms of intoxication, mobility, appearance, and autonomic nervous system, and occurrence of death.

2) Every ten days the animals' weight was measured. 3) At the termination of the experiment, all living animals were euthanized by bleeding under ether anesthesia and were observed by the naked eye. c) Results

No premature deaths were observed. Mobility was rather decreased upon application but was restored instantly. No changes in body weight were found. Autopsy opinion was that no significant eye-observable abnormalities that were suspected to be caused by contact of the skin to the compositions according to the present invention were found.

Example 8: Allergic Assessment (LLNA)

To assess allergic responses by the compositions of SBC, SBCO-1 , and SBCO-2 according to the present invention, acetone-olive oil (4:1) was used as a delivery vehicle [reference: Kimber I (1990): Identification of contact allergens using the murine local lymph node assay, J. Appl. Toxicol. 10(3); 173~180]. A mixture was made of 2mg of the compositions of SBC, SBCO-1 , and SBCO-2 according to the present invention added to 10ml of a 0.5% alcohol solution. 50μi of the mixture was applied to both ears of a mouse (Balb/c) for three days. Auricular lymph nodes were collected from the mouse and crushed to obtain single cells. The cells were cultured for 24 hours in the presence of the radiolabel [3H]thymidine, and cell proliferation was measured [cpm] as indicated in Table 12.

[Table 12]

Table 12 shows that the compositions according to the present invention induce little allergic responses, as their S.l.s were below 3.

Example 9: Irritation Test

9-1 : Irritation Test Using Guinea Pig

To assess the irritation of the compositions according to the present invention, a patch test using a guinea pig was used [reference: φDraize, J. H. (1959): Dermal toxicity. Assoc. Food and Drug officials, US. Appraisal of the safety of chemicals in Food, Drugs and Cosmetics., pp46-59, Texas State Dept of Health, Austin Texas. ©Federal Register (1973): Method of testing primary irritant substances 38(187): pp1500-1541]. Test materials to be applied were prepared by mixing the composition SBCO-2 of the present invention with distilled water in concentrations shown in Table 13.

To minimize irritation, hairs around the site on which the patch was to be applied were removed, and the guinea pig was allowed 24 hours for environment adaptation. On the patch site (1.5cm x 1.5cm in dimension), test materials and gauze were applied. A cover made of a solid substance was then placed on the patch site to prevent evaporation and loss of the test materials. The patch remained on the body with elastic bandages applied therearound for 48 hours. After the patch was removed, the degrees of irritation were observed at 2 hours and 24 hours.

[Table 13]

"PII: Primary cutaneous Irritation Index Table 13 indicates that the compositions of the present inventions are very safe to the extent that an intensive application (use of 80% concentration) caused little irritation to the skin.

9-2: Human Trial for Primary Skin Irritation (close patch)

To assess the safety of the materials including the compositions of the present invention, a human patch test (primary skin irritation) was conducted. The test materials prepared for the test were as shown in Table 14. Firstly, a test material including a 1.0% mixture of the compositions of the present invention, 1.0% of sodium lauryl sulfate, and 10% of ethanol, secondly, a test material including 1.0% of sodium lauryl sulfate, and finally, a test material including 10% of ethanol were used.

The test was conducted on 40 human subjects consisting of healthy males and females, following the guideline of CTFA (The Cosmetic, Toiletry, and Fragrance Association. Inc. Washington, D. C, 20036, 1991). 20 ml of test materials and solution was dripped in a Finn chamber and was placed on the back of a human subject. After 24 hours had elapsed, the patch was removed. Four hours after removal, the degree of irritation was determined according to the standard stated below. The results are shown in Table 14. < Standard for Determination>

- ; no erythema or otherwise distinctive symptom observed ± ; development of some red color compared to surrounding area + ; development of outstandingly red color compared to surrounding area ++ ; development of outstandingly red color compared to surrounding area and swelling

Irritation Index

[{(±)number x 1 }+{(+)number x 2}+{(++)number x 3}]/ number of subjects

[Table 14]

Table 14 indicates that a 1.0% mixture of the compositions of the present invention greatly relieved the irritation caused by 1.0% of sodium lauryl sulfate or 10% of alcohol. The result can be attributed to the excellent anti-inflammatory ability of the compositions of the present invention. That is, the results show that the compositions of the present invention are safe and are highly effective for anti-inflammation.

Claims

WHAT IS CLAIMED IS:

1. An external composition for skin, comprising sulfur, alum, and a pharmaceutically or cosmetically acceptable carrier.

2. The external composition for skin according to claim 1 , wherein the sulfur is contained in an amount of 0.001 to 5.0 parts by weight and the alum is contained in an amount of 0.5 to 8.0 parts by weight with respect to 100 parts by weight of the carrier.

3. The external composition for skin according to claim 1 , wherein the composition further comprises at least one substance selected from the group consisting of 0.5 to 5.0 parts by weight of camphor, 0.5 to 5.0 parts by weight of pine resin, 0.1 to 5.0 parts by weight of borax, 0.001 to 2.0 parts by weight of silver, and 0.5 to 10.0 parts by weight of Phellodendron amurensis with respect to 100 parts by weight of the carrier.

4. The external composition for skin according to claim 3, wherein the composition further comprises at least one substance selected from the group consisting of 0.5 to 8.0 parts by weight of cholesterol, 0.1 to 3.0 parts by weight of gypsum, 0.3 to 3.0 parts by weight of talc, and 0.5 to 5.0 parts by weight of pearl powder, with respect to 100 parts by weight of the carrier.

5. The external composition for skin according to claim 1 , wherein the sulfur is dissolved in an alkaline aqueous solution.

6. The external composition for skin according to claim 5, wherein the alkaline aqueous solution is a solution containing calcined powder of shell or an alkali metal dissolved therein.

7. The external composition for skin according to claim 1 , wherein the alum is provided in a form dissolved in water, tree sap, or deep ocean water.

8. The external composition for skin according to claim 7, wherein the tree sap is obtained from living tress selected from the group consisting of

Bambusoideae, Aceraceae, Actinidiaceae, Elaeagnaceae, Alnus japonica, and Betulaceae.

9. The external composition for skin according to claim 1 , wherein the calcined powder of shell or zeolite treated under a vacuum condition is added into solutions of said sulfur and the alum.

10. The external composition for skin according to claim 3, wherein the silver is provided in silver ionic water including 99.99% purity of silver in a concentration of 0.1g/L-20g/L, with a particle size of 2-15nm.

11. The external composition for skin according to any one of claims 1 to 4, wherein the composition further comprises 0.1 to 30.0 parts by weight of plant extract or plant oil in 100 parts by weight of the carrier, and the plant extract or plant oil is at least one selected from the group consisting of bluet, Sasa Vetchii, Lonicera japonica, horsetail, Stellaria medium, comfrey, persimmon leaves, rice bran, mulberry tree, cocoon, branch, Thladiantha dubia, hardy (trifoliate) orange, apricot, peach leaves, Benicasa hispida, pomegranate, Cupressaceae, Lespedeza bicolor, Maximowiczia chinensis, Plantago asiatica, Ligularia fischeri, Opuntia, Taraxacum mongolicum Hand-mazz, Scutellaria baicalensis G, Selaginella Tamariscina, Schizonepeta tenuifolia. var. Japonica, Coptidis Rhizoma, Commiphora molmol, Cinnamomum cassia, Angelica, Portulaca oleracea L, gingko nut, garlic, carrot, adlay, Centella asiatica, spring onion, grapefruit, rhodea, Artemisia iwayomogi, green tea, rose of Sharon, hollyhock, Saxifraga laciniata, cactus, husks, chrysanthemum, chestnut skin, Bower Actinidia, ginseng, Salix koreensis, walnut, a Japanese apricot, Xanthium strumarium, Forsythia koreana, (garden) balsam, Sophora angustifolia Sieb, Portulaca oleracea, Korean knotweed, Aconitum pseudo-laeve var, Beombuche, Solanum nigrum, Scrophularia buergeriana, Lithospermum erythrorhizon, Rubia akane Nakai, rose, Sambucus sieboldiana, trichophytia, Fraxinus sieboldiana, Pinellia ternata, Oenothera odorata, Elaeagnus umbellate, Centella Asiatica, Salicornia herbacea L., Glycyrrhiza uralensis, Callicarpa japonica Thunberg, Mirabilitum Depuratum, Paeonia lactiflora, lily, Youngreunghyang, Chamaecyparis obtusa, Arctium lappa, fruits including apples and grapes, mushrooms, beans, Adenophora, ldesia polycarpa, Ardisia crenata, Symplocos chinensis for. pilosa, Nigeulroseuporaseuperika, Zanthoxylum piperitum, Dianthus caryophyllus, Equisetum giganteum, Canna generalis, astaxanthin, Malpighia glabra, Asterias amurensis (sea star), Pinus densiflora, Betula platyphylla var. japonica, Chamomile, Marigold, Rosmarinus officinalis L., Mentha piperita (peppermint), Melissa officinalis(lemon balm), Douglas fir, Jasminum (jasmine), propolis, Allantoin, Melaleuca alternifolia, and Labiatae.

12. The external composition for skin according to claim 11 , wherein the plant extract is a solvent extract obtained by extracting the plant by at least one solvent selected from the group consisting of water, an alkaline aqueous solution, and alcohols of C1-C4, or a plant oil.

13. The external composition for skin according to any one of claims 1 to 4, wherein the composition further comprises at least one anti-inflammatory agent selected from the group consisting of flufenamic acid, ibuprofen, benzydamin, indomethacin, prednisolone, and dexamethasone, in an amount of 0.0001-2.0 parts by weight with respect to 100 parts by weight of the carrier.

14. The external composition for skin according to any one of claims 1 to 4, wherein the composition further comprises at least one antibiotic agent selected from the group consisting of Aminoglycosides, Glycopeptides, Tetracyclines, Spectinomyxin, Bacitracin, Polymyxin, and Fosfomyxin, in an amount of 0.0001- 2.0 parts by weight with respect to 100 parts by weight of the carrier.

15. The external composition for skin according to any one of claims 1 to 4, wherein the composition is in the form of liquid, suspension, gel, cream, paste, or sheet.

16. The external composition for skin according to any one of claims 1 to 4, wherein the composition is for improvement or treatment of skin disease.

17. The external composition for skin according to claim 16, wherein the skin disease is skin inflammations, acne, xerosis, tinea pedis, allergic rushes, pruritus, tinea, psoriasis, pustulosis palmaris et plantaris, or atopic diseases.

18. The external composition for skin according to any one of claims 1 to 4, wherein the composition is a cosmetic composition.

19. The external composition for skin according to claim 18, wherein the composition is in the form of skin gel, cream, lotion, powder, foundation, essence, gel, pack, foam cleanser, soap, external ointment for skin, cleansing oil, powdery foundation, liquid foundation, or wax foundation.

20. The external composition for skin according to claim 18, wherein the composition further comprises at least one additive selected from the group consisting of vitamins, amino acids, proteins, surfactants, emulsifiers, perfumes, coloring agents, stabilizers, and preservatives.

21. The external composition for skin according to any one of claims 1 to 4, wherein the carrier comprises 100 parts by weight of water, 10-30 parts by weight of the stearic acid, and 10-30 parts by weight with respect to 100 parts by weight of water.